Akeso’s Lung Cancer Drug Takes Center Stage at ASCO Plenary: What Survival Data Reveals
Akeso and Summit Therapeutics’ experimental lung cancer drug ivonescimab is the focus of Wall Street speculation ahead of ASCO’s annual meeting. The u...
Akeso and Summit Therapeutics’ experimental lung cancer drug ivonescimab is the focus of Wall Street speculation ahead of ASCO’s annual meeting. The u...
Kelonia Therapeutics, a CAR-T biotech on the brink of collapse three times, was acquired by Eli Lilly for $3.25 billion. The deal highlights the secto...
The FDA has rejected Replimune’s melanoma treatment RP1, a drug doctors say could save lives. Robert F. Kennedy Jr. denies involvement, blaming FDA Co...
Revolution Medicines presented strong clinical trial data for its next-generation KRAS inhibitor, daraxonrasib, in advanced pancreatic cancer at the A...
Revolution Medicines’ experimental KRAS drug, daraxonrasib, doubled survival rates in second-line pancreatic cancer patients compared to chemotherapy....
A new study reveals that the diabetes drug metformin may mimic a key effect of exercise in prostate cancer patients by increasing levels of an 'exerci...